HIVbio: HIV Bioinformatics |
| G.P.S. Raghava | Department of Computational Biology | IMTECH | Developers | Contact |
|
General Information Home HIVbio HIV Genome HIV Proteome HIV Life Cycles HIV Imp Enzymes Important Terms HIV Coreceptors HIV Tropism Structural Landmarks Important Databases AIDS: Therapies Drugs : HAART Drug Resistance Protein-Proteins miRNA/siRNA Therapeutics and Vaccines Miscellaneous Bioinformatics Approach Coreceptor Predictions Slides (PPT/PDF) HIV Videos Research Centres/Journals Discussions |
Drugs Against HIVAntiretroviral drugs are medications for the treatment of infection by retroviruses, primarily HIV. When several such drugs, typically three or four, are taken in combination, the approach is known as highly active antiretroviral therapy, or HAART.The drugs mainly includes : * Reverse Transcriptase Inhibitor (NRTIs/NtRTIs , NNRTIs ) * Protease Inhibitors * Fusion or Entry Inhibitors * Integrase Inhibitors NRTIs and NNRTIs are available in most countries. Fusion/entry inhibitors and integrase inhibitors are usually only available in resource-rich countries. Protease inhibitors are generally less suitable for starting treatment in resource-limited settings due to the cost, number of pills which need to be taken, and the particular side effects caused by protease drugs. There are currently more than 20 approved antiretroviral drugs in the US and Europe (including combined formulations) and many more in the expanded access programmes and trials. Most antiretroviral drugs have at least three names. Sometimes a drug is referred to by its research or chemical name, such as AZT. The second name is the generic name for all drugs with the same chemical structure; for example AZT is also known as zidovudine. The third name is the brand name given by the pharmaceutical company; one of the brand names for zidovudine is Retrovir. Lastly, an abbreviation of the common name might sometimes also be used, such as ZDV, which is the fourth name given to zidovudine. New development in HIV chemotherapy New Retroviral Drugs An Update in the Development of HIV Entry Inhibitors Raltegravir and Etravirine Are Active against HIV Type 1 Group O Strategies in design of Antiviral drugs Tharapy Insight: body-shape changes and metabolic complications associated with HIV and HAART therapy |